Raptor Pharma (RPTP) Tops Q3 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Total darkness, then sunset as full eclipse wows spectators in Spain
- Burry doubles down on Nebius short after stock surges 34% on earnings
Raptor Pharmaceutical Corp. Reports Third Quarter 2015 Financial Results and Provides Corporate Update
November 5, 2015 4:04 PM ESTRecord PROCYSBI® Product Sales of $25.8 Million
Raptor Raises 2015 PROCYSBI Revenue Guidance to $90-$95 Million
Company to Host Conference Call and Webcast Today at 4:30 p.m. EST
NOVATO, Calif., Nov. 5, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (NASDAQ: RPTP), a biopharmaceutical company developing and commercializing transformative treatments for rare diseases, today announced financial results for the three and nine months ended September 30, 2015 and provided an update on recent corporate developments.
Summary
Global net product revenue for PROCYSBI® (cysteamine bitartrate) delayed-release capsules was $25.8 million for the third... More
Raptor Pharmaceutical Corp. Reports Third Quarter 2015 Financial Results and Provides Corporate Update
November 5, 2015 4:04 PM ESTRecord PROCYSBI® Product Sales of $25.8 Million
Raptor Raises 2015 PROCYSBI Revenue Guidance to $90-$95 Million
Company to Host Conference Call and Webcast Today at 4:30 p.m. EST
NOVATO, Calif., Nov. 5, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (NASDAQ: RPTP), a biopharmaceutical company developing and commercializing transformative treatments for rare diseases, today announced financial results for the three and nine months ended September 30, 2015 and provided an update on recent corporate developments.
Summary
Global net product revenue for PROCYSBI® (cysteamine bitartrate) delayed-release capsules was $25.8 million for the third... More
